Results 311 to 320 of about 95,577 (390)

A Novel Small Molecule Enhances Stable Dopamine Delivery to the Brain in Models of Parkinson's Disease. [PDF]

Int J Mol Sci
Liu X, Hebron ML, Stevenson M, Moussa C.
europepmc   +1 more source

A Convergent Pathway for Stimulation‐Induced Dyskinesia Following Deep Brain Stimulation

Movement Disorders, EarlyView.
Abstract Background Stimulation‐induced dyskinesias (SID) from deep brain stimulation (DBS) of the subthalamic nucleus (STN) and globus pallidus internus (GPi) are uncommon; however, they are increasingly recognized. Once considered transient and indicative of effective neuromodulation, SID are now seen as potential therapy‐limiting side effects, akin ...
Joshua K. Wong, Andreas Horn, Erik H. Middlebrooks, Matthew R. Burns, Michael S. Okun   +4 more
wiley   +1 more source

Levodopa induces thyroid function regulation in a patient with thyroid hormone resistance and Parkinson's disease: a case report. [PDF]

Front Endocrinol (Lausanne)
Rozo-Paz G, Ruiz-Forero CM, Suárez-Mera JD, Monsalve Duarte G, Kattah Calderón W.   +4 more
europepmc   +1 more source

Low/High Multi‐Frequency Stimulation of the Subthalamic Nucleus Improves Verbal Fluency Maintaining Motor Control in Parkinson's Disease

Movement Disorders, EarlyView.
Abstract Background High frequency deep brain stimulation of the subthalamic nucleus (STN‐DBS) is a well‐established therapy for Parkinson's disease (PD) motor symptoms, however, its effect on non‐motor symptoms is controversial. Low frequency DBS can improve cognition, but its effects on motor functions are detrimental.
Lucia Ricciardi, Francescopaolo Cucinotta, Elena Pegolo, Arturo Abundes‐Corona, Bryony Ishihara, Israt Hossain, Zimi Sawacha, Michael Hart, Erlick Pereira, Francesca Morgante, Alfonso Fasano   +10 more
wiley   +1 more source

Decreased homovanillic acid and 5-hydroxyindoleacetic acid levels in the cerebrospinal fluid of patients with Dravet syndrome with parkinsonism. [PDF]

Epilepsia Open
Sugiyama R, Saito T, Katsumoto A, Yoneno S, Akiyama T, Komaki H.   +5 more
europepmc   +1 more source

Disease‐Modifying Trials in Treated Parkinson's Disease: “Stable Treated” Does Not Equate with Biological Stability

Movement Disorders, EarlyView.
Abstract Traditionally, clinical trials of putative disease‐modifying therapies in Parkinson's disease have enrolled untreated patients at the earliest clinical stages of their disease. Due to a number of challenges inherent with this approach, there has been a recent move to a different study design, enrolling patients who are already taking “stable ...
M. Maral Mouradian, A. Jon Stoessl, Anthony E. Lang   +2 more
wiley   +1 more source

Baseline [¹⁸F]FP-CIT PET-based deep learning prediction of levodopa-induced dyskinesia in Parkinson's disease. [PDF]

NPJ Parkinsons Dis
Lee GY, Won J, Kim S, Jo S, Lee J, Lee S, Kim JS, Sung C, Oh JS, Kim J, Kim N, Chung SJ.   +11 more
europepmc   +1 more source

Dopa-responsive parkinsonism without cerebellar ataxia in spinocerebellar ataxia 6. [PDF]

Clin Park Relat Disord
Yoshida S, Takahashi T, Suzuki N, Tobita M.   +3 more
europepmc   +1 more source

Effect of adding selegiline to levodopa in early, mild Parkinson's disease. Formal systematic review of data on patients in all relevant trials is required.

, 1998
Carl Counsell
openalex  

Changes in pancreatic levodopa uptake in patients with obesity and new-onset type 2 diabetes: an 18F-FDOPA PET-CT study. [PDF]

Front Endocrinol (Lausanne)
Kwon Y, Yoon H, Ha J, Lee HS, Pahk K, Kwon H, Kim S, Park S.   +7 more
europepmc   +1 more source